While SERMs and SERDs remain the cornerstone of ERα-positive breast cancer treatment, BRCA1 mimetics offer a novel approach by targeting tumor suppressor pathways beyond estrogen signaling. The gene discussed is ESR1; the disease is breast carcinoma.